HK1203616A1 - Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbv - Google Patents
Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbvInfo
- Publication number
- HK1203616A1 HK1203616A1 HK15104040.5A HK15104040A HK1203616A1 HK 1203616 A1 HK1203616 A1 HK 1203616A1 HK 15104040 A HK15104040 A HK 15104040A HK 1203616 A1 HK1203616 A1 HK 1203616A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hbv
- immunocomplexes
- patients
- chronic
- response prediction
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12156192.2A EP2629096A1 (fr) | 2012-02-20 | 2012-02-20 | Immuno-complexes de l'HBV pour la prédiction de la réponse et le suivi du traitement de patients souffrant de l'hépatite B chronique |
PCT/EP2013/053150 WO2013124229A1 (fr) | 2012-02-20 | 2013-02-18 | Immunocomplexes vhb utilisés pour prévoir la réponse des patients atteints d'hépatite b chronique à un traitement et surveiller ce traitement |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1203616A1 true HK1203616A1 (en) | 2015-10-30 |
Family
ID=47757571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104040.5A HK1203616A1 (en) | 2012-02-20 | 2015-04-27 | Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbv |
Country Status (7)
Country | Link |
---|---|
US (1) | US20150192583A1 (fr) |
EP (2) | EP2629096A1 (fr) |
JP (1) | JP2015508892A (fr) |
CN (1) | CN104126124A (fr) |
CA (1) | CA2863106A1 (fr) |
HK (1) | HK1203616A1 (fr) |
WO (1) | WO2013124229A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016159178A1 (fr) * | 2015-03-30 | 2016-10-06 | 雅史 溝上 | Procédé de prédiction de l'efficacité d'une thérapie basée sur l'interféron, et composition médicamenteuse destinée aux patients souffrant d'hépatite b l'utilisant |
JP2018519839A (ja) * | 2015-07-15 | 2018-07-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Hbv処置応答に関するバイオマーカー |
WO2018087715A1 (fr) * | 2016-11-11 | 2018-05-17 | Melbourne Health | Dosage pour déterminer la clairance de l'hépatite b |
WO2019123398A1 (fr) * | 2017-12-21 | 2019-06-27 | New Zealand Health Innovation Hub Management Limited | Procédé d'analyse de mutations dans le virus de l'hépatite b et utilisations de celui-ci |
WO2019213619A1 (fr) * | 2018-05-04 | 2019-11-07 | Abbott Laboratories | Méthodes et produits de diagnostic, de pronostic et de thérapie du vhb |
CN110564894B (zh) * | 2019-09-10 | 2023-04-07 | 深圳市罗湖区人民医院 | 干扰物对荧光定量pcr检测hbv dna的干扰评价方法 |
CN111474187A (zh) * | 2020-04-09 | 2020-07-31 | 三峡大学 | 一种免疫电镜免疫反应盒 |
CN115466802B (zh) * | 2022-10-28 | 2023-12-12 | 北京大学 | Tp53bp2在调控干扰素信号通路及抗病毒中的用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726011A (en) * | 1994-03-31 | 1998-03-10 | Virginia Commonwealth University | Method for diagnosing chronic hepatitis B virus infection |
WO2000078343A2 (fr) * | 1999-06-22 | 2000-12-28 | Chiron Corporation | Traitement contre l'infection par le virus de l'hepatite b |
CN1261455C (zh) * | 2002-07-19 | 2006-06-28 | 余宙耀 | 一种重组人源性抗乙肝表面抗原(HBsAg)Fab抗体及其制取方法 |
DE10339927A1 (de) * | 2003-08-29 | 2005-03-24 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen |
GB0326416D0 (en) * | 2003-11-12 | 2003-12-17 | Karolinska Innovations Ab | Methods and means relating to hepatitis B infection |
US20090170926A1 (en) * | 2004-03-31 | 2009-07-02 | Monash Univeristy | Antiviral agents |
WO2008135274A2 (fr) | 2007-05-08 | 2008-11-13 | F. Hoffmann-La-Roche Ag | Procédé de détection d'anticorps spécifiques de la classe des immunoglobulines g |
WO2010120759A1 (fr) * | 2009-04-14 | 2010-10-21 | Schering Corporation | Biomarqueurs de sensibilité aux interférons alpha |
-
2012
- 2012-02-20 EP EP12156192.2A patent/EP2629096A1/fr not_active Ceased
-
2013
- 2013-02-18 EP EP13706944.9A patent/EP2817631A1/fr not_active Ceased
- 2013-02-18 CN CN201380010278.0A patent/CN104126124A/zh active Pending
- 2013-02-18 WO PCT/EP2013/053150 patent/WO2013124229A1/fr active Application Filing
- 2013-02-18 CA CA2863106A patent/CA2863106A1/fr not_active Abandoned
- 2013-02-18 JP JP2014557064A patent/JP2015508892A/ja active Pending
-
2014
- 2014-08-19 US US14/462,802 patent/US20150192583A1/en not_active Abandoned
-
2015
- 2015-04-27 HK HK15104040.5A patent/HK1203616A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2629096A1 (fr) | 2013-08-21 |
CN104126124A (zh) | 2014-10-29 |
EP2817631A1 (fr) | 2014-12-31 |
CA2863106A1 (fr) | 2013-08-29 |
WO2013124229A1 (fr) | 2013-08-29 |
JP2015508892A (ja) | 2015-03-23 |
US20150192583A1 (en) | 2015-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180939T1 (hr) | Kombinirana terapija za liječenje multiple skleroze | |
HK1203616A1 (en) | Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbv | |
ZA201604110B (en) | New treatment of chronic ulcers | |
SG11201501075RA (en) | Medical devices for blood reflux prevention and methods of use | |
IL263661A (en) | Combination therapy for the treatment of glioblastoma | |
IL239084B (en) | Devices to support medical care | |
ZA201502503B (en) | Hppd variants and methods of use | |
EP2811897A4 (fr) | Kiosque médical et son procédé d'utilisation | |
ZA201405248B (en) | Anesthetic compounds and related methods of use | |
HK1206937A1 (en) | Methods of administering pirfenidone therapy | |
EP2906208A4 (fr) | Traitement thérapeutique | |
AU339607S (en) | Medical device for treatment of sleep disorders | |
HK1200348A1 (en) | Methods and materials for treatment of pompes disease | |
EP2867239A4 (fr) | Oxabicycloheptanes et oxabicycloheptènes pour le traitement du diabète | |
HK1210008A1 (en) | Systems and methods for treatment of sleep apnea | |
ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
RS59687B1 (sr) | Oblici doziranja i terapeutske primene l-4-hlorkinurenina | |
IL245604A0 (en) | Combination treatment of anti-mif antibodies and chemotherapeutic agents | |
GB201201778D0 (en) | Treatment of inflammatory respiratory disease | |
EP2854878A4 (fr) | Dispositif médical pour le traitement de plaies |